Stem-Cell Transplantation for Myelofibrosis

Publisher Website
Google Scholar
Abstract
In response to Tefferi's excellent review of myelofibrosis (April 27 issue),1 Guardiola and colleagues have provided the results of allogeneic stem-cell transplantation in their patients with myelofibrosis (Aug. 31 issue).2 The authors refer to a previous report,3 which included data on 55 patients who underwent transplantation at a number of institutions, including the Fred Hutchinson Cancer Research Center; they then provide information on 11 new patients (with no indication as to where those patients underwent transplantation) and present a brief analysis of the results in all 66 patients. These results show an estimated five-year overall survival rate of 62 percent among patients who were younger than 45 years of age and 14 percent among patients who were 45 years of age or older. This outcome leads the authors to conclude that transplantation may not be the optimal strategy in patients who are 45 years of age or older. If transplantation is planned at all, it should be carried out at a younger age.

This publication has 2 references indexed in Scilit: